Protalix BioTherapeutics (FRA:PBDA) Moat Score: 4/10 (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PBDA Protalix BioTherapeutics Inc FRA:PBDA
56 GF Score
Price €2.00
GF Value €1.89
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Protalix BioTherapeutics Moat Score?

Protalix BioTherapeutics FRA:PBDA +2.15% 56 Moat Score is 4 as of Aug. 19, 2026. GuruFocus rates FRA:PBDA with a GF Score™ of 56/100 and a GF Value™ of €1.89 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,388 Biotechnology companies, Protalix BioTherapeutics ranks better than 88.76% on this metric.

Protalix BioTherapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Protalix BioTherapeutics has Narrow Moat: Protalix BioTherapeutics Inc has a discernible but modest moat due to its proprietary technology in biopharmaceuticals and some valuable intellectual property. However, it lacks strong brand strength, significant regulatory barriers, and customer switching costs, limiting its competitive advantages to a narrow category.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Protalix BioTherapeutics might have Narrow Moat - Discernible but modest moat.

Protalix BioTherapeutics  (FRA:PBDA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Protalix BioTherapeutics Moat Score Related Terms

FRA:PBDA vs GLSI, DTIL, NERV: Moat Score Comparison

For the Biotechnology subindustry, Protalix BioTherapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protalix BioTherapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Moat Score falls into.


FRA:PBDA
56GF Score
Protalix BioTherapeutics Inc FRA:PBDA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Protalix BioTherapeutics (FRA:PBDA) has a Moat Score of 4 as of Aug. 19, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Protalix BioTherapeutics ranks #156 out of 1388 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Protalix BioTherapeutics' Moat Score too high?
Protalix BioTherapeutics' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Protalix BioTherapeutics' value of 4 is 100% above this industry median. Based on the distribution chart, Protalix BioTherapeutics ranks #156 out of 1388 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Protalix BioTherapeutics has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' Moat Score compare to GLSI and DTIL?
According to the Biotechnology industry distribution chart, Protalix BioTherapeutics ranks #156 out of 1388 companies for Moat Score. This places Protalix BioTherapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Protalix BioTherapeutics' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,388 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protalix BioTherapeutics's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protalix BioTherapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (FRA:PBDA) is currently considered Fairly Valued. The stock's GF Value™ is €1.89, compared to a current price of €2.00 — trading 5.8% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Protalix BioTherapeutics' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Protalix BioTherapeutics (FRA:PBDA), the current Moat Score is 4 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protalix BioTherapeutics (FRA:PBDA) Overvalued in 2026?

Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued. The current stock price of €2.00 is trading 5.8% above its estimated GF Value™ of €1.89. GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.

Key valuation signals for FRA:PBDA:

  • Moat Score: 4
  • GF Value™: €1.89 vs. price of €2.00 (5.8% above fair value)
  • GF Score™: 56/100 with 4 warning signs
  • Industry Position: 100% above the Biotechnology median (#156 of 1388)

No single metric tells the full story. See the FRA:PBDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protalix BioTherapeutics Business Description

Other Exchanges PLX:USA
Address 2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
56GF Score

Get the complete analysis for FRA:PBDA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.00
Price
€1.89
GF Value